Alkylating agent prodrugs for ADEPT

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 331-340

  Burke, P J ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

ADEPT; alkylating agents; enzymes; prodrugs

Indexed keywords

ANTIBODIES; AROMATIC COMPOUNDS; DISEASES; DRUG PRODUCTS; ENZYMES; GRAFTS;

ALKYLATING AGENTS; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; AROMATIC NITROGEN MUSTARDS; CANCER THERAPY; PRODRUGS; TUMOUR; TUMOUR XENOGRAFT MODELS;

DRUG THERAPY;

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALKALINE PHOSPHATASE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; BETA LACTAMASE; CARBOXYPEPTIDASE G2; CHLORMETHINE DERIVATIVE; ENZYME; MELPHALAN; MITOMYCIN C; MONOCLONAL ANTIBODY; NITROREDUCTASE; PENICILLIN AMIDASE; PRODRUG;

ANIMAL MODEL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER GRAFT; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; XENOGRAFT;

EID: 0030589608     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00446-2     Document Type: Review

References (30)

1. [1] Haskel, C.M. (Ed). (1985) Cancer Treatment, 2nd edition. W.B. Saunders, New York.
2. [2] Frei, E., Teicher, B.A., Holden, S.A., Cathcart, N.K.S. and Wang, Y. (1988) Preclinical studies and clinical correlation of the effect of alkylating agent dose. Cancer Res. 48, 6417-6423.
3. [3] Bagshawe, K.D. (1987) Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 56, 531-532.
4. [4] Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
5. [5] Antoniw, P., Springer, C.J., Bagshawe, K.D., Searle, F., Melton, R.G., Rogers, G.T., Burke, P.J. and Sherwood, R.F. (1990) Disposition of the prodrug 4-(bis(2-chloroethyl)amino)benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer 62, 909-914.
6. [6] Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M.F. and Jarman, M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33, 677-681.
7. [7] Springer, C.J., Antoniw, P., Bagshawe, K.D. and Wilman, D.E.V. (1991) Comparison of half-lives and cytotoxicity of W-chloroethyl-4-amino and N-mesyloxyethyl benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-cancer drug design 6, 467-479.
8. [8] Springer, C.J., Bagshawe, K.D., Sharma, S.K., Searle, F., Boden, J.A., Antoniw, P., Burke, P.J., Rogers, G.T., Sherwood, R.F. and Melton, R.G. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366
9. [9] Blakey, D.C., Valcaccia, B.E., East, S., Wright, A.F., Boyle, F., Springer, C.J., Burke, P.J., Melton, R.G. and Bagshawe, K.D. (1993) Antitumour effects of an antibody carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys. 222, 1-8.
10. [10] Sharma, S.K., Boden, J.A., Springer, C.J., Burke, P.J. and Bagshawe, K.D. (1994) Antibody directed enzyme prodrug therapy (ADEPT): a three phase study in ovarian tumour xenografts. Cell Biophys. 24/25, 219-228.
11. [11] Eccles, S.A., Court, W.J., Box, G.A., Dean, C.J., Melton, R.G. and Springer, C.J. (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 54, 5171-5177.
12. [12] Springer, C.J., Niculescu-Duvaz, I. and Pedley, R.B. (1994) Novel prodrugs of alkylating agents derived from 2-fluoro-and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem. 37, 2361-2370.
13. [13] Blakey, D.C., Davies, D.H., Dowell, R.I., East, S.J., Burke, P.J., Sharma, S.K., Springer, C.J., Mauger, A.B. and Melton, R.G. (1995) Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br. J. Cancer 72, 1083-1088.
14. [14] Springer, C.J., Dowell, R., Burke, P.J., Hadley, E., Davies, D. H., Blakey, D.C., Melton, R.G. and Niculescu-Duvaz, I. (1995) Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J. Med. Chem. 38, 5051-5065.
15. [15] Burke, P.J., Blakey, D.C., Sharma, S.K., Davies, D.H., Dowell, R.J., East, S.J., Springer, C.J. and Melton, R.G. (1994) Proceedings of the American Association for Cancer Research. Abstract 2873.
16. [16] Wallace, P.M. and Senter, P.D. (1991) In vitro and in vivo activities of monodonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2, 349-352.
17. [17] Senter, P.D., Schreiber, I.G., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E. and Hellstrom, I. (1989) Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49, 5789-5792.
18. [18] Wang, S.M., Chern, J.W., Yeh, M.Y., Ng, J.C., Tung, E. and Roffler, S.R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52, 4484-4491.
19. [19J Roffler, S.R., Wang, S.M., Chern, J.W., Yeh, M.Y. and Tung, E. (1991) Anti-neoplastic glucuronide prodrug treatment of human tumour cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. 42, 2062-2065.
20. [20] Alexander, R., Beeley, N.R.A., O'Driscoll, M., O'Neill, F.P., Millican, T.A., Praft, A.J. and Willenbrock, F.W. (1991) Cephalosporin nitrogen mustard carbamate prodrugs for ADEPT. Tetrahedron Lett. 32, 3269-3272.
21. [21] Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M. and Senter, P.D. (1992) Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem. 3, 176-181.
22. [22] Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D. and Wallace, P.M. (1993) Anti-tumour activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem. 4, 334-340.
23. [23] Kerr, D.E., Schreiber, G.J., Vrudhula, V.M., Svensson, H.P., Hellstrom, I., Hellstrom, K.E. and Senter, P.D. (1995) Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 55, 3558-3563.
24. [24] Hanessian, S. and Wang, J. (1993) Design and synthesis of a cephalosporin carboplatinum prodrug activatable by a β-lactamase. Can. J. Chem. 71, 896-906.
25. [25] Bristol Myers Co. (1992) European patent application 0 484 870 A2.
26. [26] Kerr, D.A., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellstrom, I. and Hellstrom, K. (1990) Antibody-penicillin-V-amidase conjugates kill antigen positive cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31, 202-205.
27. [27] Vrudhula, V.M., Senter, P.D., Fischer, K.J. and Wallace, P.M. (1993) Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin G amidase conjugate. J. Med. Chem. 36, 919-923.
28. [28] Mauger, A.B., Burke, P.J., Somani, H.H., Friedlos, F. and Knox, R.J. (1994) Self immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37, 3452-3458.
29. [29] Sunters, A., Baer, J. and Bagshawe, K.D. (1991) Cytotoxicity and activation of CB1954 in a human tumour cell line. Biochem. Pharmacol. 41, 1293-1298.
30. [30] Knox, R.J., Friedlos, F. and Boland, M.P. (1993) The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy. Cancer Metastasis Rev. 12, 195-212.